Rhumbline Advisers bought a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 16,721 shares of the company’s stock, valued at approximately $275,000.
Separately, Moody Aldrich Partners LLC bought a new position in shares of Upstream Bio during the 4th quarter worth approximately $1,229,000.
Upstream Bio Price Performance
Shares of UPB stock opened at $8.94 on Monday. The stock’s 50 day moving average is $10.56. Upstream Bio, Inc. has a 52 week low of $6.65 and a 52 week high of $29.46.
About Upstream Bio
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
- Five stocks we like better than Upstream Bio
- 3 Dividend Kings To Consider
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- How to Calculate Options Profits
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- Pros And Cons Of Monthly Dividend Stocks
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Want to see what other hedge funds are holding UPB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Upstream Bio, Inc. (NASDAQ:UPB – Free Report).
Receive News & Ratings for Upstream Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Upstream Bio and related companies with MarketBeat.com's FREE daily email newsletter.
